Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1260

Sort by

Sort Order Select

Journal Articles

CD44 loss of function sensitizes AML cells to the BCL-2 inhibitor venetoclax by decreasing CXCL12-driven survival cues

Xiaobing Yu, Leonel Munoz-Sagredo, Karolin Streule, Patricia Muschong, Elisabeth Bayer, Romina J. Walter, Julia C. Gutjahr, Richard Greil, Miguel L. Concha, Carsten Müller-Tidow, Tanja N. Hartmann, Véronique Orian-Rousseau

Blood (2021) 138 (12): 1067–1080.

https://doi.org/10.1182/blood.2020006343

Published: 2021

Includes: Multimedia, Supplemental data

Journal Articles

Extracellular vesicles shed by follicular lymphoma B cells promote polarization of the bone marrow stromal cell niche

Erwan Dumontet, Céline Pangault, David Roulois, Matthis Desoteux, Simon Léonard, Tony Marchand, Maelle Latour, Patricia Legoix, Damarys Loew, Florent Dingli, Joelle Dulong, Erwan Flecher, Cédric Coulouarn, Guillaume Cartron, Thierry Fest, Karin Tarte

Blood (2021) 138 (1): 57–70.

https://doi.org/10.1182/blood.2020008791

Published: 2021

Includes: Supplemental data

Journal Articles

RUNX2 Regulates Cell Migration in T-Cell Lineage Acute Lymphoblastic Leukemia

Nitesh Devinarayan Sharma, PhD, Christian C. Nickl, Huining Kang, PhD, Wojciech Ornatowski, PhD, Stuart S. Winter, MD, Mignon L. Loh, MD, Stephen P. Hunger, MD, Ksenia Matlawska-Wasowska, PhD

Blood (2019) 134 (Supplement_1): 3947.

https://doi.org/10.1182/blood-2019-129337

Published: 2019

Journal Articles

Synergistic Targeting of BTK and E-Selectin/CXCR4 in the Microenvironment of Mantle Cell Lymphomas

Mahesh Basyal, Weiguo Zhang, MD PhD, Nalini B Patel, Sujan Piya, PhD, Hongying Zhang, MD PhD, William E. Fogler, PhD, William G Rice, PhD, John L. Magnani, PhD, Gautam M. Borthakur, MD, Michael Andreeff, MD PhD

Blood (2019) 134 (Supplement_1): 3802.

https://doi.org/10.1182/blood-2019-126030

Published: 2019

Journal Articles

IFNy Stimulation Induces Hematopoietic Stem Cell Homing and Niche Relocalization

Marcus A Florez, BS, Katie A Matatall, PhD, Laura Ortinau, PhD, Roman Jaksik, PhD, Marek Kimmel, PhD DSc, Dongsu Park, PhD, Katherine Y. King, MD PhD

Blood (2019) 134 (Supplement_1): 3726.

https://doi.org/10.1182/blood-2019-130555

Published: 2019

Journal Articles

Interrogating the Spatial Architecture of Human Bone Marrow Via Imaging Mass Cytometry

Karolyn A. Oetjen, MD, Diane E. Bender, PhD, Marianna B. Ruzinova, MD PhD, Stephen T. Oh, MD, Daniel C. Link, MD

Blood (2019) 134 (Supplement_1): 3728.

https://doi.org/10.1182/blood-2019-127460

Published: 2019

Journal Articles

The Distinctive Metabolic Environment of the Bone Marrow Niche Drives Leukemia Chemoresistance

Nick van Gastel, PhD, Jessica B. Spinelli, PhD, Azeem Sharda, MS, Amir Schajnovitz, PhD, Ninib Baryawno, PhD, Catherine S Rhee, PhD, Toshihiko Oki, MD PhD, Eliane Grace, Heather J. Soled, Charles Vidoudez, PhD, Sunia A. Trauger, PhD, Marcia C. Haigis, PhD, David T. Scadden, MD

Blood (2019) 134 (Supplement_1): 3725.

https://doi.org/10.1182/blood-2019-124789

Published: 2019

Journal Articles

Inhibition of Anti-Apoptotic Mcl-1 Exerts Anti-Leukemia Activity through Modulation of Leukemia-Stromal Interactions and Metabolic Functions in AML

Bing Z Carter, PhD, Po Yee Mak, Marc Warmoes, Wenjing Tao, Philip Lorenzi, Vivian Ruvolo, MS, Lin Tan, Justin Cidado, PhD, Lisa Drew, PhD, Michael Andreeff, MD PhD

Blood (2019) 134 (Supplement_1): 3727.

https://doi.org/10.1182/blood-2019-124453

Published: 2019

Journal Articles

CXCR4 Inhibition with BL-8040 in Combination with Nelarabine in Patients with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia / Lymphoblastic Lymphoma

Geoffrey L. Uy, MD, Tapan M. Kadia, MD, Wendy Stock, MD, Jonathan E Brammer, MD, Osnat Bohana-Kashtan, PhD, Abi Vainstein, Ella Sorani, PhD, Hemda Chen, PharmD, John F. DiPersio, MD PhD, Daniel C. Link, MD

Blood (2019) 134 (Supplement_1): 2630.

https://doi.org/10.1182/blood-2019-127121

Published: 2019

Journal Articles

Tipifarnib Modulates Interferon (IFN)-γ-Inducible Genes in Acute Myeloid Leukemia

Jayakumar Vadakekolathu, PhD, Stephen Reeder, BSc, Clare Coveney, PhD, Sergio Rutella, MDPhDFRCPath

Blood (2019) 134 (Supplement_1): 2726.

https://doi.org/10.1182/blood-2019-124717

Published: 2019

Journal Articles

Cxcr4 low FLT3/ITD + Cells Exhibit Enhanced Resistance to the FLT3 Inhibitor Quizartinib Compared to Cxcr4 high FLT3/ITD + Cells By Elevating Runx1 Expression

Seiji Fukuda, MD PhD, Chie Onishi, MD PhD, Takeshi Taketani, MD

Blood (2019) 134 (Supplement_1): 2558.

https://doi.org/10.1182/blood-2019-129513

Published: 2019

Journal Articles

Intravital Imaging of Bright Cyan-Fluorescent AML Model Reveals Impact of CXCR4 Inhibitor on AML and Immune Cell Dynamics

Tomasz Zal, PhD, Mateusz Rytelewski, PhD, Rodrigo Jacamo, PhD, Malgorzata Anna Zal, MSc, Meenakshi Shanmugasundaram, Michael Andreeff, MD PhD

Blood (2019) 134 (Supplement_1): 2674.

https://doi.org/10.1182/blood-2019-131945

Published: 2019

Journal Articles

CXCR4 Blockade By BL-8040 in T Cell Acute Lymphoblastic Leukemia Decreases Mitochondrial Mass and Induces Non-Apoptotic Cell Death

Jun Xia, PhD, Stephanie Sun, Matthew RM Jotte, Geoffrey L. Uy, MD, Osnat Bohana-Kashtan, PhD, Ella Sorani, PhD, Abi Vainstein, Amnon Peled, PhD, Daniel C. Link, MD

Blood (2019) 134 (Supplement_1): 2745.

https://doi.org/10.1182/blood-2019-128881

Published: 2019

Journal Articles

Distinct Bone Marrow Microenvironment Abnormalities in MDS and MPN with Fibrosis

Cao Sy Luan, MS, Yoshiaki Takahoko, MS, Hidekazu Nishikii, MD PhD, Naoshi Obara, MD PhD, Tatsuhiro Sakamoto, MD PhD, Takayasu Kato, MD PhD, Keiichiro Hattori, MD PhD, Ryota Matsuoka, MD PhD, Shingo Sakashita, MD PhD, Yasuhito Nannya, MD PhD, Hideki Makishima, MD PhD, Mamiko Sakata-Yanagimoto, MD PhD, Seishi Ogawa, MD PhD, Shigeru Chiba, MD PhD

Blood (2019) 134 (Supplement_1): 2976.

https://doi.org/10.1182/blood-2019-129423

Published: 2019

Journal Articles

Therapeutic Targeting of CCR1 to Prevent Dissemination of Multiple Myeloma Plasma Cells

Mara N Zeissig, BS, Duncan R Hewett, PhD, Krzysztof M Mrozik, PhD, Vasilios Panagopoulos, PhD, Monika Engelhardt, MD, Luen Bik To, MBBS, FRACP, FRCPA, PhD, Peter J Croucher, PhD, Andrew CW Zannettino, PhD, Kate Vandyke, PhD

Blood (2019) 134 (Supplement_1): 3099.

https://doi.org/10.1182/blood-2019-121974

Published: 2019

Journal Articles

Inducible SBDS Deficiency Impairs Bone Marrow Niche Function to Engraft Donor Hematopoietic Stem Cell after Transplantation

Ji Zha, PhD BS, Lori Kunselman, Hongbo Michael Xie, PhD, Brian Ennis, Jian-Meng Fan, Timothy S. Olson, MD PhD

Blood (2019) 134 (Supplement_1): 3199.

https://doi.org/10.1182/blood-2019-121763

Published: 2019

Journal Articles

Upregulation of Senescent/Exhausted Phenotype of CAR T Cells and Induction of Both Treg and Myeloid Suppressive Cells Correlate with Reduced Response to CAR T Cell Therapy in Relapsed/Refractory B Cell Malignancies

Katia Beider, Michal J Besser, PhD, Jacob Schachter, MD, Ania Hava Grushchenko-Polaq, Valeria Voevoda, Idit Wolf, Olga Ostrovsky, PhD, Elad Jacoby, MD, Avichai Shimoni, MD, Arnon Nagler, MD MSc

Blood (2019) 134 (Supplement_1): 3234.

https://doi.org/10.1182/blood-2019-128068

Published: 2019

Journal Articles

Updated Study Results of CX-01, an Inhibitor of CXCL12/CXCR4, and Azacitidine for the Treatment of Hypomethylating Agent Refractory AML and MDS

Eric Huselton, MD, Amanda F Cashen, MD, John F. DiPersio, MD PhD, Meagan Jacoby, MD, Iskra Pusic, MD, Rizwan Romee, MD PhD, Mark A. Schroeder, MD, Geoffrey L. Uy, MD, Peter Westervelt, MD PhD

Blood (2019) 134 (Supplement_1): 3915.

https://doi.org/10.1182/blood-2019-132065

Published: 2019

Journal Articles

The mTOR Component, Rictor, Is Regulated By the Microenvironment to Control Dormancy and Proliferative States in Myeloma Cells

Syed J. Mehdi, PhD, Sarah K Johnson, PhD, Tarun K. Garg, PhD, Cody Ashby, PhD, Maurizio Zangari, MD, Carolina D. Schinke, MD, Sharmilan Thanendrarajan, MD, Joshua Epstein, DSc, Brian A Walker, PhD, Frits van Rhee, MD PhD, Shmuel Yaccoby, PhD

Blood (2019) 134 (Supplement_1): 4412.

https://doi.org/10.1182/blood-2019-127382

Published: 2019

Journal Articles

The JAK1/2 Inhibitor Ruxolitinib Downregulates CXCL12 Secretion from Bone Marrow Stromal Cells and M2 Macrophage Polarization in Multiple Myeloma

Haiming Chen, MD PhD, Mingjie Li, BS, Eric Sanchez, BA, Nicole Ng, BS, Erin Yu, BS, Sean Bujarski, BA, Zhengyi Yin, Tara Hekmati, Dylan Field, Jasper Wang, Isabella Nassir, Justin Huang, David Daniely, Cathy S. Wang, BS, Ning Xu, PhD, James R. Berenson, MD

Blood (2019) 134 (Supplement_1): 4352.

https://doi.org/10.1182/blood-2019-131324

Published: 2019

NARROW

CD44 loss of function sensitizes AML cells to the BCL-2 inhibitor venetoclax by decreasing CXCL12-driven survival cues

Extracellular vesicles shed by follicular lymphoma B cells promote polarization of the bone marrow stromal cell niche

RUNX2 Regulates Cell Migration in T-Cell Lineage Acute Lymphoblastic Leukemia

Synergistic Targeting of BTK and E-Selectin/CXCR4 in the Microenvironment of Mantle Cell Lymphomas

IFNy Stimulation Induces Hematopoietic Stem Cell Homing and Niche Relocalization

Interrogating the Spatial Architecture of Human Bone Marrow Via Imaging Mass Cytometry

The Distinctive Metabolic Environment of the Bone Marrow Niche Drives Leukemia Chemoresistance

Inhibition of Anti-Apoptotic Mcl-1 Exerts Anti-Leukemia Activity through Modulation of Leukemia-Stromal Interactions and Metabolic Functions in AML

CXCR4 Inhibition with BL-8040 in Combination with Nelarabine in Patients with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia / Lymphoblastic Lymphoma

Tipifarnib Modulates Interferon (IFN)-γ-Inducible Genes in Acute Myeloid Leukemia

Cxcr4 low FLT3/ITD + Cells Exhibit Enhanced Resistance to the FLT3 Inhibitor Quizartinib Compared to Cxcr4 high FLT3/ITD + Cells By Elevating Runx1 Expression

Intravital Imaging of Bright Cyan-Fluorescent AML Model Reveals Impact of CXCR4 Inhibitor on AML and Immune Cell Dynamics

CXCR4 Blockade By BL-8040 in T Cell Acute Lymphoblastic Leukemia Decreases Mitochondrial Mass and Induces Non-Apoptotic Cell Death

Distinct Bone Marrow Microenvironment Abnormalities in MDS and MPN with Fibrosis

Therapeutic Targeting of CCR1 to Prevent Dissemination of Multiple Myeloma Plasma Cells

Inducible SBDS Deficiency Impairs Bone Marrow Niche Function to Engraft Donor Hematopoietic Stem Cell after Transplantation

Upregulation of Senescent/Exhausted Phenotype of CAR T Cells and Induction of Both Treg and Myeloid Suppressive Cells Correlate with Reduced Response to CAR T Cell Therapy in Relapsed/Refractory B Cell Malignancies

Updated Study Results of CX-01, an Inhibitor of CXCL12/CXCR4, and Azacitidine for the Treatment of Hypomethylating Agent Refractory AML and MDS

The mTOR Component, Rictor, Is Regulated By the Microenvironment to Control Dormancy and Proliferative States in Myeloma Cells

The JAK1/2 Inhibitor Ruxolitinib Downregulates CXCL12 Secretion from Bone Marrow Stromal Cells and M2 Macrophage Polarization in Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only